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Abstract
Deposition of amyloid plaques in the brain is one of the two main pathological hallmarks of 
Alzheimer’s disease (AD). Amyloid positron emission tomography (PET) is a neuroimaging tool 
that selectively detects in vivo amyloid deposition in the brain and is a reliable endophenotype for 
AD that complements cerebrospinal fluid biomarkers with regional information. We measured in 
vivo amyloid deposition in the brains of ~1,000 subjects from three collaborative AD centers and 
ADNI using 11C-labeled Pittsburgh Compound-B (PiB)-PET imaging followed by meta-analysis 
of genome-wide association studies, first to our knowledge for PiB-PET, to identify novel genetic 
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loci for this endophenotype. The APOE region showed the most significant association where 
several SNPs surpassed the genome-wide significant threshold with APOE*4 most significant (P-
meta=9.09E-30; β=0.18). Interestingly, after conditioning on APOE*4, 14 SNPs remained 
significant at P<0.05 in the APOE region that were not in linkage disequilibrium with APOE*4. 
Outside the APOE region, the meta-analysis revealed 15 non-APOE loci with P<1E-05 on nine 
chromosomes, with two most significant SNPs on chromosomes 8 (P-meta=4.87E-07) and 3 (P-
meta=9.69E-07). Functional analyses of these SNPs indicate their potential relevance with AD 
pathogenesis. Top 15 non-APOE SNPs along with APOE*4 explained 25%−35% of the amyloid 
variance in different datasets; of which 14–17% was explained by APOE*4 alone. In conclusion, 
we have identified novel signals in APOE and non-APOE regions that affect amyloid deposition in 
the brain. Our data also highlights the presence of yet to be discovered variants that may be 
responsible for the unexplained genetic variance of amyloid deposition.
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INTRODUCTION
Genomic efforts mainly through large-scale genome-wide association studies (GWAS), as 
part of the Alzheimer’s Disease Genetics Consortium (ADGC)1 and the International 
Genomics of Alzheimer’s Project (IGAP)2 have identified over 20 genes/loci for late-onset 
Alzheimer’s disease (AD). However, known common AD variants account for only ~30% of 
the AD genetic variance3 and they also do not provide definitive information about 
underlying disease mechanisms. Genetic studies focusing on AD-related quantitative 
phenotypes/endophenotypes may help to identify additional AD-related genes. One such 
AD-related phenotype is deposition of amyloid-beta (Aβ) in the brain, which is one of the 
two main pathologic hallmarks of AD; the other being the formation of tau deposits in the 
form of neurofibrillary tangles, neuropil threads and dystrophic neurites (tau pathology) in 
the brain.4 According to the current model for sporadic AD, Aβ pathology occurs 
independently of tau pathology, is detectable earlier and is believed to accelerate neocortical 
tau pathology and neurodegeneration.5 Recent longitudinal studies on cognitively normal 
subjects also confirm that amyloidosis is an early process in AD.6, 7 The in vivo detection of 
Aβ deposition in the brain, as measured by positron emission tomography (PET) scanning 
with 11C-labeled Pittsburgh Compound-B (PiB) and the increased retention of PiB observed 
in the brains of AD patients compared to cognitively normal controls, was first reported by 
Klunk and colleagues8, 9 and since has been confirmed in many studies.10 There is a high 
correlation between amyloid PET imaging and neuritic plaque frequency as confirmed by 
autopsy studies.11–13 Multiple studies have shown that amyloid PET has a high value for the 
clinical diagnosis of AD and in clinical trials aiming to reduce brain Aβ burden.14
There is a well-established association of APOE variants with risk1, 2 and age-at-onset15, 16 
of AD. Likewise, APOE genetic variation is also strongly associated with Aβ deposition in 
the brain as measured by PiB retention,17–19 indicating a genetic basis of Aβ deposition in 
the brain. Here, we used PiB-PET as an endophenotype to identify novel genetic loci for AD 
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pathology using meta-analysis of three GWAS, the first to our knowledge, using the largest 
sample with the PiB-PET imaging from three different centers and the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI).
MATERIALS AND METHODS
Sample description
All subjects with PiB-PET data were European-Americans and derived from three sites: 
University of Pittsburgh (PITT), Washington University (WU) and Indiana University (IU) 
combined with the initial phase of the multicenter ADNI PiB-PET add-on study (here they 
are referred to as ADNI/IU). All subjects provided informed consent and all studies were 
approved by their local Institutional Review Boards. The summary statistics of these 
samples are included in Supplementary Table S1 and their description is given 
Supplementary Text.
Amyloid-PET data
Detailed methods for acquisition and processing of PiB-PET scans are described in previous 
reports for the PITT,17, 18 WU,19 ADNI20–22 and IU23 studies. PiB retention was measured 
in 4 cortical regions of the brain, including medial frontal cortex (MFC; anterior cingulate/
gyrus rectus), lateral frontal cortex (LFC), precuneus cortex (PRC) and parietal cortex (PAR) 
and expressed as a ratio to the cerebellum. In the GWAS meta-analysis, the PiB retention 
values from these 4 cortical regions were averaged in each subject to calculate a mean global 
score (GBL4) as the quantitative endophenotype. PiB retention was expressed as 
standardized uptake volume ratio (SUVR) in the PITT and ADNI/IU data23, 24 and as 
binding potential (BP) in the WU data.25 BP is approximately equal to SUVR-1. Because of 
this inconsistency in the PiB measurement methods the GWAS data were analyzed via P-
value based meta-analysis as described below.
Genotyping, imputation and quality control
The genotyping platforms used for each study sample are listed in Supplementary Table S1. 
Imputation of non-genotyped single-nucleotide polymorphisms (SNPs) was performed with 
IMPUTE226 using the 1000 Genomes Project27 Phase III (May 2013 release) data as the 
reference panel for PITT and Phase I (November 2010 release) data for WU and ADNI/IU 
datasets. Full description of these procedures is given in Supplementary Text.
Meta-analysis
METAL28 software was used to perform meta-analysis on three GWAS using the mean PiB-
PET GBL4 value. METAL performs a P-value based meta-analysis, which is appropriate 
when the effects being estimated are different in different cohorts. It does, however, account 
for differences in sample size between cohorts and for the direction of effects. The summary 
effect size was calculated by averaging the study-specific effect sizes, with weights 
reflecting the standard errors from the study-specific effect sizes.
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Functional analyses
To evaluate the biological significance of PiB-associted signals, we conducted five different 
analyses: differential gene expression in AD versus non-AD in relevant tissues, brain gene 
expression, expression quantitative trait loci (eQTL) analyses, summary-data-based 
Mendelian randomization (SMR) analyses to test for pleiotropic association between gene 
expression and PiB, and pathway analyses. Detailed description of these analyses is given in 
Supplementary Text.
RESULTS
Amyloid PET data characteristics
The characteristics of participants in each of the three datasets included in the meta-analysis 
are shown in Supplementary Table S1. The WU sample was younger with less male 
participants. The distribution of mean global PiB retention is shown in Figure 1.
GWAS Analysis
Quantile-quantile (QQ) plots and lambda values for the meta-analysis showed that neither 
the results from each of the three component studies nor the combined results from meta-
analysis were inflated in their test statistics (Figure 2a). Meta-analysis revealed 27 genome-
wide significant SNPs (P<5E-08) in a four-gene region on chromosome 19: PVRL2-
TOMM40-APOE-APOC1(Figure 2b, and Supplementary Table S2). As expected, APOE*4/
rs429358 showed the most significant association with the average global PiB retention (P-
meta=9.09E-30; β=0.18; Figure 3, Supplementary Figure S1).
Outside of the APOE region, no genome-wide significant signal was observed. However, the 
meta-analysis revealed 15 non-APOE loci with P<1E-05 on chromosomes 8, 3, 15, 4, 21, 13, 
2, 12 and 1 (Table 1). Most of these loci show quite consistent results across the all datasets. 
The regional plots of these 15 non-APOE loci are shown in Supplementary Figures S2.1-
S2.15. The most significant SNP outside the APOE region is intergenic located between 
ADCY8 - EFR3A on chromosome 8 (rs13260032; P=4.87E-07, Supplementary Figure 
S2.1). The next most significant SNP is also intergenic located between RAP2B - C3orf79 
on chromosome 3 (rs4680057; P=9.69E-07, Supplementary Figure S2.2). Chromosome 3 
also harbors two additional signals: one in ncRNA (LINC00971/rs9831119; P=2.98E-06, 
Supplementary Figure S2.6) and another near MAGEF1/ rs11923588 (P=5.66E-06, Figure 
S2.9). The third most significant SNP is located in the DAPK2 gene on chromosome 15 
(rs12908891; P=1.39E-06, Supplementary Figure S2.3). We also analyzed the data after 
adjusting for the effect of APOE*4/rs429358 in these non-APOE regions, which showed a 
slight attenuation of the association strengths (Table 1).
Conditional Analysis in the APOE Region
In order to check if there were independent SNPs associated with the PiB retention in the 
APOE region, we performed conditional analysis by adjusting for the top SNP (APOE*4/
rs429358). A total of 14 SNPs remained significant at P<0.05 (Table 2), including 3 SNPs 
that showed genome-wide significance before adjusting for APOE*4 (rs75627662, rs483082 
and rs438811; Supplementary Table S2). Supplementary Figure S3 shows LD structure of 
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these 14 SNPs along with APOE*4/rs429358 and APOE*2/rs7412 SNPs. APOE*4 and 
APOE*2 have essentially no LD with 9 of the 14 SNPs that are located in the PVRL2 gene 
(SNPs 1–9 in Supplementary Figure S3). One SNP located in the APOE/APOC1 intergenic 
region (rs59325138) has only very weak correlation with APOE*4 (R2=0.15) and APOE*2 
(R2=0.03). While 3 SNPs located down stream of APOE and APOE/APOC1 intergenic 
region have weak to moderate LD with APOE*4 (R2=0.42, 0.64, 0.65 for rs75627662, 
rs483082 and rs438811, respectively).
The most significant SNP in meta-conditional analysis was APOE*2/rs7412 (P-
meta=3.69E-03; β=−0.06; Table 2), though it was not genome-wide significant before 
adjusting for APOE*4 (P-meta=6.57E-05; β=−0.09). A similar strength of association was 
seen with an intronic PVRL2/rs3852859 SNP after adjusting for APOE*4 (P-meta=8.8E-03; 
β=0.06; Table 2) that was in LD with 3 additional SNPs (SNPs 1, 7, 9 in Supplementary 
Figure S3). Three additional apparently independent associations were seen with rs4803767 
(P-meta=2.06E-02; β=0.05 Table 2) that was in LD with 4 additional SNPs (SNPs 2–5 in 
Supplementary Figure S3), rs75627662 (P-meta=1.50E-02; β=−0.03; Table 2) that was in 
LD with 2 additional SNPs (SNPs 13,15 in Supplementary Figure S3) and rs59325138 (P-
meta=3.10E-02; β=0.03; Table 2) that has very weak correlation with all other SNPs 
(R2=0.01– 0.24).
Association of known AD risk loci with amyloid burden and Association of amyloid loci 
with AD risk
We examined the top IGAP genome-wide significant SNPs (Supplementary Table S3.1) and 
the associated gene regions (Supplementary Table S3.2) in relation to amyloid burden and 
found only some nominally significance SNPs. Likewise, we examined the suggestive non-
APOE amyloid loci in our PITT-ADRC case-control sample of >2,200 subjects29 and found 
association of two top amyloid-associated SNPs with AD risk (Supplementary Table S4.1). 
When we examined additional Aβ-associated SNPs in each region with AD risk, we found 
multiple associations with P<0.05 (Supplementary Table S4.2), indicating that our 
suggestive Aβ-associated loci are also associated with AD risk (see Supplementary Text for 
more details).
Estimation of Amyloid-PET variance by APOE and non-APOE loci
The genetic variance was estimated based on the R-square calculated from a linear 
regression model regressing global PiB retention on 6 independent APOE SNPs (rs429358, 
rs7412, rs3852859, rs4803767, rs75627662, rs59325138), as described above, and 15 non-
APOE SNPs given in Table 1. The contribution of 6 APOE SNPs to the variance of global 
PiB retention was 28.0%, 17.3% and 17.12% in the PITT, WU and ADNI/IU datasets, 
respectively; APOE*4/rs429358 alone explained 17.5%, 16.5% and 13.9%, respectively. The 
top 15 non-APOE SNPs explained 22.6%, 21.6% and 21.7% of the amyloid variance in the 
PITT, WU and ADNI/IU datasets, respectively. The consistency of these estimates across the 
different datasets gives confidence that the difference in measurement of PiB across the 
datasets does not affect the bottom-line results.
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Functional analyses
We performed five analyses (see Methods section) to evaluate the biological significance of 
PiB-implicated signals/genes. We considered all genes within ±500kb of the top variant in 
each locus from Table 1 plus any eQTL-controlled genes outside the ±500kb boundary as 
target genes (Figure 3, Supplementary Figures S2.1-S2.15), and selected a total of 257 
genes.
Of 257 target genes, we found 20 upregulated and 25 downregulated genes that were 
differentially expressed in the same direction in two or more AD studies and no opposite 
directions were reported (Table 3 and Supplementary Table S6 marked in green color). Brain 
RNA-seq data reveals many of these differentially expressed candidate genes are expressed 
in AD-relevant cell types (Table 3 and Supplementary Table S6 marked in yellow color).
For eQTL analyses, we identified SNPs in LD (R2 ≥ 0.5) with the top SNP for each locus in 
Table 1. For these SNPs, there were cis-acting eQTLs (eQTL P <0.05) for 151 of the 257 
target genes in various brain tissues, and 36 genes in whole blood available in GTEx. 
Supplementary Table S5 gives the eQTL results for each top SNP in 15 non-APOE loci and 
the detailed results of LD SNPs (R2≥0.80) with top SNPs are given in Supplementary Table 
S7. With the exception of SLITRK1 /rs9831119, the other 14 top SNPs were eQTLs in 
different brain regions; 11 of them were eQTL in anterior cingulate cortex/frontal cortex/
cortex where PiB intake is highest,30 indicating their role in affecting amyloid deposition in 
the brain.
For SMR analyses, only the gene/variant pairs identified in the cis-eQTL analyses were 
considered. For these gene/variant pairs, 99 genes in any brain tissue and 19 in whole blood 
were shown to mediate genetic effects on PiB by cis-regulating gene expression (SMR P 
<0.05; Table 3, Supplementary Table S6).
We conducted pathway analyses (MAGMA31) using four gene set resources, including and 
excluding target genes in the APOE region, and detected nine genome-wide significant 
pathways: ndkdynamin pathway, FDR= 4.6E-04; synaptic vesicle recycling, FDR= 3.5E-07; 
synaptic vesicle endocytosis, FDR= 3.1E-04; protein depolymerization, FDR= 3.1E-04; 
inositol tetrakisphosphate phosphatase activity, FDR= 5.7E-03; positive regulation of 
vacuole organization, FD = 5.7E-03; inositol trisphosphate phosphatase activity, FDR= 
0.033; regulation of clathrin-mediated endocytosis, FDR= 0.038; and clathrin-mediated 
endocytosis, FDR = 0.043. Although none of the 257 target genes, including APOE, are 
included in these nine genome-wide significant pathways, 71 target genes are included in the 
nominally significant pathways and 46 target genes are included in the non-APOE region-
related nominally significant pathways (P < 0.05. Table 3 and Supplementary Table S6 
marked in pink color).
DISCUSSION
In this investigation, we have used the largest PiB-PET imaging data (n=~1,000), available 
from multiple collaborative centers, as an endophenotype to identify novel genetic loci for 
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AD pathology using the GWAS meta-analysis approach, the first to our knowledge for PiB-
PET.
The APOE region showed the most significant association where several SNPs surpassed the 
genome-wide significant threshold (P<5E-08) with APOE*4 as the top hit that was 
associated with higher PiB retention in the brain (P-meta=9.09E-30; β=0.18). APOE*2, a 
protective genetic factor against AD, was associated with lower PiB retention, albeit, not 
genome-wide significant (P-meta=6.57E-05; β=−0.09). This observation is consistent with 
earlier reports of the association of the APOE* 2/3/4 polymorphism with Aβ deposition in 
the brain as measured by PiB-PET17–19 or florbetapir-PET.32 Likewise, a GWAS of 
cerebrospinal fluid (CSF) Aβ has identified a genome-wide significant SNP that was a proxy 
for APOE*4.33 Numerous prior studies have investigated the role of the APOE* 2/3/4 
polymorphism on Aβ production, aggregation and clearance in the brain,34 but recent 
studies provide solid mechanistic clues into the role of APOE genetic variation in affecting 
APP transcription and Aβ production,35 and seeding of amyloid pathology.36 In addition to 
the APOE*2/3/4 association, conditional analysis on APOE*4 identified 14 independent 
signals in the APOE region that also affect brain amyloidosis. Nine of 14 SNPs had 
essentially no LD with APOE*4 and APOE*2 and the remaining 5 showed moderate to 
weak LD with APOE*4. Thus, our meta-analysis indicates the presence of additional signals 
in the APOE region, beyond the APOE*4/rs429358 and APOE*2/rs7412 SNPs, that affect 
Aβ deposition in the brain.
Outside the APOE region, the meta-analysis revealed 15 suggestive non-APOE loci with 
P<1E-05 on nine chromosomes. Although they do not meet the established genome-wide 
significance criteria, their consistent and directional associations in three independent 
datasets (Table 1) suggest that at least some of them are likely candidate loci for brain 
amyloidosis process and/or AD risk and variants in these loci may have achieved the 
genome-wide significance threshold in larger datasets. Credence to this idea was provided 
by our observation that most of these suggestive loci were also associated with AD risk 
when we examined the Aβ-associated SNPs in a published AD GWAS29 (Supplementary 
Tables S4.1-S4.2). The most significant non-APOE SNP (rs13260032; P=4.87E-07) on 
chromosomes 8 is intergenic, and this was an eQTL for a nearby ADCY8 gene in frontal 
cortex, which is one of the highest PiB uptake cortical regions.30 ADCY8 is essential to 
long-term potentiation and synaptic plasticity and is implicated in memory and learning.37 
Genetic variation in or around ADCY8 has shown to be associated with dissociation 
symptoms in subjects with posttraumatic stress disorder,37 abdominal visceral38 and alcohol-
dependent depression.39 The second top SNP (rs4680057; P=9.69E-07) resides near C3orf79 
and was an eQTL for a nearby long noncoding RNA (lncRNA) gene in anterior cingulate 
cortex and hippocampus in the brain and for ARHGEF26 in blood. lncRNAs play a critical 
role in gene regulatory networks and may affect diverse biological processes and diseases,40 
including AD where several IncRNAs have been shown to regulate Aβ production/
generation.41, 42 A recent GWAS has identified ARHGEF26 as a new genetic factor for 
coronary artery disease risk that influences the transendothelial migration of leukocytes.43 
The third top SNP (rs12908891; P=1.39E-06) is located DAPK2 on chromosome 15 that 
belongs to a family of related serine/threonine kinases shown to be involved in multiple 
functions, including apoptosis, autophagy, tumor suppression and inflammation.44 Although 
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the role of DAPK2 in amyloidosis in unknown, another family member, DAPK1, promotes 
the phosphorylation and amyloidogenic processing of APP.45 The DAPK2 region contains 
other candidate genes, such as GSNK1G1 and TRIP4. While TRIP4 is a known gene for 
AD,46 GSNK1G1 has been implicated in the formation of Aβ.47 The top SNP was the most 
significant eQTL for HERC1 gene expression in anterior cingulate cortex (P=7.02E-05; 
P_SMR=1.94E-03). HERC1 belongs to the ubiquitin–proteasome system that plays a key 
role in the protein degradation pathway essential for neuronal homeostasis, synaptic 
development and maintenance. Mutations in HERC1 have been associated with intellectual 
disability48 and autism spectrum disorders.49
To identify additional PiB-relevant candidate genes, we combined results from the brain 
expression, differential brain expression in AD, eQTL/SMR in the brain, and pathway 
analyses. Four genes meeting all these functional criteria were identified: RPS27L in the 
DAPK2 region, CYP4V2 and TLR3 in the CYP4V2 region, and IDH1 in the IDH1/C2orf80 
region (Table 3, Supplementary Table S6). RPS27L is an evolutionarily conserved ribosomal 
protein and a physiological regulator of transcription factor p53 that is involved in genomic 
stability and tumor suppression.50 p53 has also been implicated in AD progression, in part, 
due to its interaction with Aβ in AD progression.51 p53 also interact with IDH1 in 
glioblastoma.52 It seems that the involvement of RPS27L and IDH1 in the amyloidogenic 
process is through their effect on or interaction with p53. Although the role of CYP4V2 in 
amyloidosis is currently unclear, activated TLR3, along with some members of the toll-like 
receptors family, can induce Aβ uptake or inflammatory response during the AD 
progression.53 Further functional characterization of these candidate genes may help to 
elucidate their roles in brain amyloidosis.
A recent GWAS using CSFAβ42 as an endophenotype has identified two novel loci in 
addition to the APOE locus.33 One locus is near GLIS1 on chromosome 1 and the other in 
SERPINB1 on chromosome 6. The reported GLIS1/185031519 SNP was neither present in 
our genotyping array nor was it imputed. This SNP was also not in high LD with other 
SNPs. On the other hand, the reported SERPINB1/rs316341 SNP was present in our data, 
but it was not significant (P=0.148). We also examined four additional reported SERPINB1 
SNPs with P<1E-05 (rs316339, rs316337, rs392120, rsrs2293772)33 and found one of them 
to be nominally significant in our data (rs392120; P=0.033).
We estimated the genetic variance of global PiB retention explained by the APOE and top 15 
non-APOE SNPs with P<1E-05 using a linear regression model. The non-APOE SNPs along 
with APOE*4 explained 25%−35% of the amyloid variance; of which 14–17% was 
explained by APOE*4 alone. A previous study using a different amyloid tracer (florbetapir-
PET)32 found a similar contribution of APOE*4 (11%) to amyloid variance. However, a 
GWAS on CSF Aβ42 found a smaller contribution of APOE*4 (4%) to amyloid variance.33 
This may be due to the use of different methods to estimate the amyloid variance. While the 
CSF study used the Genome-wide Complex Trait Analysis (GCTA) that requires >3,000 
sample size,54 the two amyloid tracer studies with smaller sample sizes used linear 
regression. Our data, in conjunction with previous studies, highlight the presence of yet to be 
discovered variants that may be responsible for the unexplained genetic variance of amyloid 
deposition.
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As with any genome-wide study, this study has limitations. Although the present study used 
the largest combined sample of PiB-PET imaging data reported to-date (from three different 
centers and ADNI), the sample size was relatively small to achieve genome-wide 
significance for loci with small effect sizes. We predict that at least some of our suggestive 
loci with P<1E-05 might have achieved genome-wide significance with a larger sample size, 
as the direction of allelic effects for all suggestive loci were consistent in all datasets. Unlike 
some other phenotypes where data could be obtained readily on large numbers of subjects at 
a relatively low-cost, this is not the case with amyloid PET. Thus, the lack of a very large 
PiB-PET imaging database for a genome-wide study was a significant constraint. As more 
PiB-PET imaging data are obtained by different centers, future collaborative studies, as done 
here, on larger samples may allow the identification of additional genes for brain 
amyloidosis.
In conclusion, this is the first GWAS on PiB-PET that has confirmed the established 
association of the APOE locus with in vivo brain amyloidosis. In addition to the known 
association, we have identified novel variants in the APOE region that affect amyloidosis. A 
combination of genetic and functional approaches has also led to the identification of 
additional putative candidate genes that warrant follow-up genetic and functional studies to 
confirm their role in brain amyloidosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Distribution of PiB retention in the University of Pittsburgh (PITT) (A), Washington 
University (WU) (B), and the Alzheimer’s disease Neuroimaging Initiative (ADNI) and the 
Indiana Memory and Aging Study (ADNI/IU) (C) samples. SUVR= Standardized Uptake 
Volume Ratio; BP= Binding Potential
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Figure 2a. 
Quantile-quantile plot for the individual GWAS results in the University of Pittsburgh 
(PITT), Washington University (WU), and the Alzheimer’s disease Neuroimaging Initiative 
(ADNI) and the Indiana Memory and Aging Study (ADNI/IU) datasets and in the meta-
analysis. λ is the genomic control value.
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Figure 2b. 
Manhattan plot showing the P-values in the meta-analysis. The blue line represents the 
suggestive significance line (P<E-05). The red line represents the significance threshold 
(P<5E-08).
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Figure 3. 
Regional plot of the APOE region on chromosome 19 in the meta-analysis. The relative 
location of genes and the direction of transcription are shown in the lower portion of the 
figure, and the chromosomal position is shown on the x -axis. The light blue line show the 
recombination rate across the region (right y -axis), and the left y axis shows the significance 
of the associations. The purple diamond shows the P-value for rs429358 that is the most 
significant SNP in the meta-analysis. The circles show the P-values for all other SNPs and 
are color coded according to the level of LD with rs429358 in the 1000 Genome Project 
EUR population.
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